A general framework for inhibitor resistance in protein kinases

Chemistry and Biology

Volumn 18, Issue 8, 2011, Pages 966-975

  Balzano, Deborah ^a   Santaguida, Stefano ^a   Musacchio, Andrea ^a,b   Villa, Fabrizio ^a  

^a EUROPEAN INSTITUTE OF ONCOLOGY   (Italy)

^b MAX PLANCK INSTITUTE OF MOLECULAR PHYSIOLOGY   (Germany)

Author keywords

[No Author keywords available]

Indexed keywords

5 IODOTUBERCIDIN; 5-IODOTUBERCIDIN; CSK TYROSINE PROTEIN KINASE; CSK TYROSINE-PROTEIN KINASE; DRUG DERIVATIVE; PROTEIN KINASE; PROTEIN KINASE INHIBITOR; PROTEIN TYROSINE KINASE; TUBERCIDIN;

AMINO ACID SEQUENCE; ANIMAL; ARTICLE; CHEMICAL STRUCTURE; DRUG ANTAGONISM; DRUG RESISTANCE; GENETICS; HELA CELL; HUMAN; METABOLISM; MOLECULAR GENETICS; MUTATION; SEQUENCE ALIGNMENT;

AMINO ACID SEQUENCE; ANIMALS; DRUG RESISTANCE; HELA CELLS; HUMANS; MODELS, MOLECULAR; MOLECULAR SEQUENCE DATA; MUTATION; PROTEIN KINASE INHIBITORS; PROTEIN KINASES; PROTEIN-TYROSINE KINASES; SEQUENCE ALIGNMENT; TUBERCIDIN;

PYRONIA TITHONUS;

EID: 80052163881     PISSN: 10745521     EISSN: None     Source Type: Journal    
DOI: 10.1016/j.chembiol.2011.04.013     Document Type: Article

References (47)

1. D.G. Aguilera, and A.M. Tsimberidou Dasatinib in chronic myeloid leukemia: a review Ther. Clin. Risk Manag. 5 2009 281 289
2. J.A. Bikker, N. Brooijmans, A. Wissner, and T.S. Mansour Kinase domain mutations in cancer: implications for small molecule drug design strategies J. Med. Chem. 52 2009 1493 1509
3. A.C. Bishop, O. Buzko, and K.M. Shokat Magic bullets for protein kinases Trends Cell Biol. 11 2001 167 172 (Pubitemid 32295922)
4. S. Blencke, B. Zech, O. Engkvist, Z. Greff, L. Orfi, Z. Horvath, G. Keri, A. Ullrich, and H. Daub Characterization of a conserved structural determinant controlling protein kinase sensitivity to selective inhibitors Chem. Biol. 11 2004 691 701 (Pubitemid 38708838)
5. S. Branford, Z. Rudzki, S. Walsh, A. Grigg, C. Arthur, K. Taylor, R. Herrmann, K.P. Lynch, and T.P. Hughes High frequency of point mutations clustered within the adenosine triphosphate-binding region of BCR/ABL in patients with chronic myeloid leukemia or Ph-positive acute lymphoblastic leukemia who develop imatinib (STI571) resistance Blood 99 2002 3472 3475 (Pubitemid 34525335)
6. R. Capdeville, E. Buchdunger, J. Zimmermann, and A. Matter Glivec (STI571, imatinib), a rationally developed, targeted anticancer drug Nat. Rev. Drug Discov. 1 2002 493 502
7. T.A. Carter, L.M. Wodicka, N.P. Shah, A.M. Velasco, M.A. Fabian, D.K. Treiber, Z.V. Milanov, C.E. Atteridge, W.H. Biggs 3rd, and P.T. Edeen Inhibition of drug-resistant mutants of ABL, KIT, and EGF receptor kinases Proc. Natl. Acad. Sci. USA 102 2005 11011 11016 (Pubitemid 41105984)
8. Y.L. Choi, M. Soda, Y. Yamashita, T. Ueno, J. Takashima, T. Nakajima, Y. Yatabe, K. Takeuchi, T. Hamada, and H. Haruta EML4-ALK mutations in lung cancer that confer resistance to ALK inhibitors N. Engl. J. Med. 363 2010 1734 1739
9. P. Cohen Protein kinases: the major drug targets of the twenty-first century? Nat. Rev. Drug Discov. 1 2002 309 315 (Pubitemid 37361447)
10. J.A. Cooper, and A. MacAuley Potential positive and negative autoregulation of p60c-src by intermolecular autophosphorylation Proc. Natl. Acad. Sci. USA 85 1988 4232 4236
11. J. Dai, S. Sultan, S.S. Taylor, and J.M. Higgins The kinase haspin is required for mitotic histone H3 Thr 3 phosphorylation and normal metaphase chromosome alignment Genes Dev. 19 2005 472 488 (Pubitemid 40256279)
12. H. Daub, K. Specht, and A. Ullrich Strategies to overcome resistance to targeted protein kinase inhibitors Nat. Rev. Drug Discov. 3 2004 1001 1010 (Pubitemid 39642363)
13. J. Eswaran, D. Patnaik, P. Filippakopoulos, F. Wang, R.L. Stein, J.W. Murray, J.M. Higgins, and S. Knapp Structure and functional characterization of the atypical human kinase haspin Proc. Natl. Acad. Sci. USA 106 2009 20198 20203
14. C.E. Fitzgerald, S.B. Patel, J.W. Becker, P.M. Cameron, D. Zaller, V.B. Pikounis, S.J. O'Keefe, and G. Scapin Structural basis for p38alpha MAP kinase quinazolinone and pyridol-pyrimidine inhibitor specificity Nat. Struct. Biol. 10 2003 764 769 (Pubitemid 37052417)
15. F. Girdler, F. Sessa, S. Patercoli, F. Villa, A. Musacchio, and S. Taylor Molecular basis of drug resistance in aurora kinases Chem. Biol. 15 2008 552 562 (Pubitemid 351815053)
16. M.E. Gorre, M. Mohammed, K. Ellwood, N. Hsu, R. Paquette, P.N. Rao, and C.L. Sawyers Clinical resistance to STI-571 cancer therapy caused by BCR-ABL gene mutation or amplification Science 293 2001 876 880 (Pubitemid 32743979)
17. J.H. Hanke, J.P. Gardner, R.L. Dow, P.S. Changelian, W.H. Brissette, E.J. Weringer, B.A. Pollok, and P.A. Connelly Discovery of a novel, potent, and Src family-selective tyrosine kinase inhibitor. Study of Lck- and FynT-dependent T cell activation J. Biol. Chem. 271 1996 695 701
18. J.M. Higgins Structure, function and evolution of haspin and haspin-related proteins, a distinctive group of eukaryotic protein kinases Cell. Mol. Life Sci. 60 2003 446 462 (Pubitemid 36459525)
19. C.H. Hung, L. Thomas, C.E. Ruby, K.M. Atkins, N.P. Morris, Z.A. Knight, I. Scholz, E. Barklis, A.D. Weinberg, and K.M. Shokat HIV-1 Nef assembles a Src family kinase-ZAP-70/Syk-PI3K cascade to downregulate cell-surface MHC-I Cell Host Microbe 1 2007 121 133 (Pubitemid 46554916)
20. M.W. Karaman, S. Herrgard, D.K. Treiber, P. Gallant, C.E. Atteridge, B.T. Campbell, K.W. Chan, P. Ciceri, M.I. Davis, and P.T. Edeen A quantitative analysis of kinase inhibitor selectivity Nat. Biotechnol. 26 2008 127 132
21. A.E. Kelly, C. Ghenoiu, J.Z. Xue, C. Zierhut, H. Kimura, and H. Funabiki Survivin reads phosphorylated histone H3 threonine 3 to activate the mitotic kinase Aurora B Science 330 2010 235 239
22. Z.A. Knight, and K.M. Shokat Features of selective kinase inhibitors Chem. Biol. 12 2005 621 637 (Pubitemid 43142039)
23. S. Kobayashi, T.J. Boggon, T. Dayaram, P.A. Janne, O. Kocher, M. Meyerson, B.E. Johnson, M.J. Eck, D.G. Tenen, and B. Halmos EGFR mutation and resistance of non-small-cell lung cancer to gefitinib N. Engl. J. Med. 352 2005 786 792 (Pubitemid 40271173)
24. R. Krishnamurty, and D.J. Maly Biochemical mechanisms of resistance to small-molecule protein kinase inhibitors ACS Chem. Biol. 5 2010 121 138
25. Y. Liu, and N.S. Gray Rational design of inhibitors that bind to inactive kinase conformations Nat. Chem. Biol. 2 2006 358 364 (Pubitemid 43936934)
26. G. Manning, D.B. Whyte, R. Martinez, T. Hunter, and S. Sudarsanam The protein kinase complement of the human genome Science 298 2002 1912 1934 (Pubitemid 35425239)
27. J.V. Melo, and C. Chuah Resistance to imatinib mesylate in chronic myeloid leukaemia Cancer Lett. 249 2007 121 132 (Pubitemid 46452920)
28. T. Nagai, K. Ibata, E.S. Park, M. Kubota, K. Mikoshiba, and A. Miyawaki A variant of yellow fluorescent protein with fast and efficient maturation for cell-biological applications Nat. Biotechnol. 20 2002 87 90 (Pubitemid 34044921)
29. B. Okram, A. Nagle, F.J. Adrian, C. Lee, P. Ren, X. Wang, T. Sim, Y. Xie, G. Xia, and G. Spraggon A general strategy for creating "inactive- conformation" abl inhibitors Chem. Biol. 13 2006 779 786 (Pubitemid 44109805)
30. W. Pao, V.A. Miller, K.A. Politi, G.J. Riely, R. Somwar, M.F. Zakowski, M.G. Kris, and H. Varmus Acquired resistance of lung adenocarcinomas to gefitinib or erlotinib is associated with a second mutation in the EGFR kinase domain PLoS Med. 2 2005 e73
31. F.E. Parkinson, and J.D. Geiger Effects of iodotubercidin on adenosine kinase activity and nucleoside transport in DDT1 MF-2 smooth muscle cells J. Pharmacol. Exp. Ther. 277 1996 1397 1401 (Pubitemid 27167151)
32. G. Rena, J. Bain, M. Elliott, and P. Cohen D4476, a cell-permeant inhibitor of CK1, suppresses the site-specific phosphorylation and nuclear exclusion of FOXO1a EMBO Rep. 5 2004 60 65 (Pubitemid 38228529)
33. S. Santaguida, A. Tighe, A.M. D'Alise, S.S. Taylor, and A. Musacchio Dissecting the role of MPS1 in chromosome biorientation and the spindle checkpoint through the small molecule inhibitor reversine J. Cell Biol. 190 2010 73 87
34. T. Schindler, W. Bornmann, P. Pellicena, W.T. Miller, B. Clarkson, and J. Kuriyan Structural mechanism for STI-571 inhibition of abelson tyrosine kinase Science 289 2000 1938 1942
35. P.J. Scutt, M.L. Chu, D.A. Sloane, M. Cherry, C.R. Bignell, D.H. Williams, and P.A. Eyers Discovery and exploitation of inhibitor-resistant aurora and polo kinase mutants for the analysis of mitotic networks J. Biol. Chem. 284 2009 15880 15893
36. M.A. Seeliger, M. Young, M.N. Henderson, P. Pellicena, D.S. King, A.M. Falick, and J. Kuriyan High yield bacterial expression of active c-Abl and c-Src tyrosine kinases Protein Sci. 14 2005 3135 3139 (Pubitemid 41770154)
37. N.P. Shah, C. Tran, F.Y. Lee, P. Chen, D. Norris, and C.L. Sawyers Overriding imatinib resistance with a novel ABL kinase inhibitor Science 305 2004 399 401 (Pubitemid 38938156)
38. D.A. Sloane, M.Z. Trikic, M.L. Chu, M.B. Lamers, C.S. Mason, I. Mueller, W.J. Savory, D.H. Williams, and P.A. Eyers Drug-resistant aurora A mutants for cellular target validation of the small molecule kinase inhibitors MLN8054 and MLN8237 ACS Chem. Biol. 5 2010 563 576
39. J.E. Smart, H. Oppermann, A.P. Czernilofsky, A.F. Purchio, R.L. Erikson, and J.M. Bishop Characterization of sites for tyrosine phosphorylation in the transforming protein of Rous sarcoma virus (pp60v-src) and its normal cellular homologue (pp60c-src) Proc. Natl. Acad. Sci. USA 78 1981 6013 6017 (Pubitemid 12247455)
40. S. Soverini, G. Martinelli, S. Colarossi, A. Gnani, F. Castagnetti, G. Rosti, C. Bosi, S. Paolini, M. Rondoni, and P.P. Piccaluga Presence or the emergence of a F317L BCR-ABL mutation may be associated with resistance to dasatinib in Philadelphia chromosome-positive leukemia J. Clin. Oncol. 24 2006 e51 e52
41. K. Suryanarayan, S.P. Hunger, S. Kohler, A.J. Carroll, W. Crist, M.P. Link, and M.L. Cleary Consistent involvement of the bcr gene by 9;22 breakpoints in pediatric acute leukemias Blood 77 1991 324 330
42. T. Tamaoki, H. Nomoto, I. Takahashi, Y. Kato, M. Morimoto, and F. Tomita Staurosporine, a potent inhibitor of phospholipid/Ca++dependent protein kinase Biochem. Biophys. Res. Commun. 135 1986 397 402 (Pubitemid 16049425)
43. F. Villa, P. Capasso, M. Tortorici, F. Forneris, A. de Marco, A. Mattevi, and A. Musacchio Crystal structure of the catalytic domain of Haspin, an atypical kinase implicated in chromatin organization Proc. Natl. Acad. Sci. USA 106 2009 20204 20209
44. F. Wang, J. Dai, J.R. Daum, E. Niedzialkowska, B. Banerjee, P.T. Stukenberg, G.J. Gorbsky, and J.M. Higgins Histone H3 2010 Thr-3
45. S. Wong, and O.N. Witte The BCR-ABL story: bench to bedside and back Annu. Rev. Immunol. 22 2004 247 306 (Pubitemid 38680424)
46. Y. Yamagishi, T. Honda, Y. Tanno, and Y. Watanabe Two histone marks establish the inner centromere and chromosome bi-orientation Science 330 2010 239 243
47. J. Zhang, P.L. Yang, and N.S. Gray Targeting cancer with small molecule kinase inhibitors Nat. Rev. Cancer 9 2009 28 39